Trial · NCT07897890
Registered outcomes22
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 20 of 22
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of participants enrolled and retained | End of treatment at 8 weeks after baseline | The percentage of breast cancer survivors who enrolled in the study and were retained at post-treatment (0-100%; higher percentage = more retained) |
| Primary | Attendance rates (Acceptability) | Weekly attendance at each of the 8 THRIVE NOW sessions from baseline to last session | Percentage of sessions that participants attended in person and/or made-up (0-100%; higher percentage = higher attendance) |
| Primary | Acceptability (Program Evaluation) | End of treatment at 8 weeks after baseline | Scores on the Treatment Acceptability/Adherence Scale (TAAS) (10-70; higher scores = greater acceptability/adherence ratings) |
| Secondary | Fat mass | From baseline to the end of treatment at 8 weeks | Change in fat mass (kg) from baseline to post-treatment measured using the InBody 270 Bio-electrical Impedance Device |
| Secondary | Cancer-related symptom (fatigue severity) | From baseline to the end of treatment at 8 weeks | Fatigue severity using the Fatigue Symptom Inventory (FSI) (0-10; with higher scores = more severe fatigue) |
| Secondary | Cancer-related symptom (fatigue interference) | From baseline to the end of treatment at 8 weeks | Fatigue interference using the Fatigue Symptom Inventory (FSI) (0-70; with higher scores = more fatigue interference) |
| Secondary | Cancer-related symptoms (pain severity) | From baseline to the end of treatment at 8 weeks | Pain severity assessed using the PROMIS Pain Intensity Short Form (T-score 50 +/- 10; higher scores = greater pain severity) |
| Secondary | Cancer-related symptoms (pain interference) | From baseline to the end of treatment at 8 weeks | Pain interference assessed using the PROMIS Pain Interference Short Form (T-score 50 +/- 10; higher scores = greater pain interference) |
| Secondary | Processed Food Consumption | From baseline to the end of treatment at 8 weeks | Processed food consumption measure using the Screening Questionnaire of Highly Processed Food Consumption (sQ-HPF; 0-14; greater scores = higher processed food consumption) |
| Secondary | Physical Activity | From baseline to the end of treatment at 8 weeks | MET-Minutes from the Self-reported International Physical Activity Questionnaire (IPAQ; MET/min; higher scores = more physical activity) |
| Secondary | Psychological Inflexibility | From baseline to the end of treatment at 8 weeks | Scores on the Multidimensional Psychological Flexibility Inventory (MPFI; 1-6; greater scores = more inflexibility) |
| Other | Skeletal Muscle Mass | From baseline to the end of treatment at 8 weeks | Changes in skeletal muscle mass (kg) from baseline to post-treatment measured using the InBody 270 Bio-electrical Impedance Device |
| Other | Total Body Weight | From baseline to the end of treatment at 8 weeks | Changes in total body weight (kg) from baseline to post-treatment measured using the InBody 270 Bio-electrical Impedance Device |
| Other | Body Fat Percentage | Baseline to post-treatment (8 weeks after baseline) | Change in body fat percentage from baseline to post-treatment measured using the InBody 270 Bio-electrical Impedance Device |
| Other | Body Mass Index | Baseline to post-treatment (8 weeks after baseline) | Change in body mass index (BMI; kg/m2) from baseline to post-treatment measured using the InBody 270 Bio-electrical Impedance Device |
| Other | Depressive symptoms | Baseline to post-treatment (8 weeks after baseline) | Scores on the Patient Health Questionnaire-8 (0-24; greater scores = greater depressive symptoms) |
| Other | Anxiety symptoms | Baseline to post-treatment (8 weeks after baseline) | Scores on the Generalized Anxiety Disorder-7 (0-21; greater scores = greater anxiety symptoms) |
| Other | Well-being | Baseline to post-treatment (8 weeks after baseline) | Scores on the BBC Subjective Well-Being Scale (24-120; greater scores = greater well-being) |
| Other | Eating Disorder Symptoms | From baseline to the end of treatment at 8 weeks | Total scores on the Eating Disorder Examination - Questionnaire (EDE-Q; 0-6; higher scores = greater eating disorder psychopathology) |
| Other | Internalized Weight Stigma | From baseline to the end of treatment at 8 weeks | Scores on the Modified Weight Bias Internalization Scale (WBIS-M; 1-7; higher scores = greater internalization of weight stigma) |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT07897890/registered